France to warn 1.6 million desogestrel users about a small meningioma risk

A nationwide safety notification

France's medicines agency is preparing to write to about 1.6 million women who have used desogestrel-based contraception, informing them of a small increased risk of meningioma. Euronews reported that approximately 90,000 prescribing doctors will also receive information. The action turns an earlier European pharmacovigilance decision into a large national communication campaign affecting patients who use several common contraceptive brands.

The warning concerns meningioma, a tumour arising in the membranes surrounding the brain and spinal cord. Most meningiomas are non-cancerous and slow-growing, but their position or size can produce serious neurological effects. French guidance identified persistent headaches, changes in vision, muscle weakness, problems with balance or speech, memory loss and new or worsening seizures as symptoms that should prompt medical consultation.

Low absolute risk, targeted precautions

Regulators emphasise that the absolute risk remains very low. Euronews cited French research estimating approximately one additional case associated with desogestrel for every 67,000 users overall, with higher risk after prolonged treatment. The European Medicines Agency separately estimated one additional meningioma for every 67,300 women using desogestrel- or etonogestrel-containing products, demonstrating why authorities are communicating caution without describing the medicines as broadly unsafe.

The EMA's Pharmacovigilance Risk Assessment Committee recommended updated product information after reviewing a large French epidemiological study. The new measures make the medicines unsuitable for patients who currently have, or previously had, a meningioma. They also instruct clinicians to consider prior exposure to other progestogens associated with the tumour and to discontinue the medicine if a meningioma is diagnosed.

What patients and clinicians should do

French authorities are not advising patients to stop contraception on their own. An abrupt, unplanned change can create other health consequences, including unintended pregnancy. Instead, users are being told to discuss their individual history, duration of treatment and any concerning symptoms with a doctor, gynaecologist or midwife. Contraceptive choices should be reassessed regularly, with imaging considered when symptoms or medical history justify it.

The next stage is implementation: letters must reach patients, prescribers must incorporate the revised contraindications, and product information must accurately communicate both the risk and its small magnitude. Pharmacovigilance systems will continue monitoring reported cases and the effects of prolonged exposure. The development is consequential public-health regulation, but it is neither a military strike nor a ceasefire and therefore carries no map alert.